Page last updated: 2024-12-05

alpha-aminobutyric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

alpha-aminobutyric acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

alpha-aminobutyric acid : An alpha-amino acid that is butyric acid bearing a single amino substituent located at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

D-alpha-aminobutyric acid : An optically active form of alpha-aminobutyric acid having D-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID439691
CHEMBL ID553426
CHEBI ID28797
SCHEMBL ID427560
MeSH IDM0059124

Synonyms (66)

Synonym
(r)-2-aminobutanoate
AC-1209
d-2-aminobutanoate
(2r)-2-aminobutanoic acid
(2r)-2-aminobutyric acid
CHEBI:28797 ,
d-2-aminobuttersaeure
(r)-2-aminobutyric acid
d-alpha-aminobutyric acid
d-(-)-2-aminobutyric acid
2r-amino-butanoic acid
LMFA01100043
alpha-aminobutyric acid
d-2-aminobutyrate
d-2-aminobutyric acid ,
2623-91-8
d-2-aminobutanoic acid
C02261
(r)-2-aminobutanoic acid
DB04454
A3B ,
d-2-aminobutyric acid, 98%
A-5200
(r)-(-)-2-aminobutyric acid
A1377
CHEMBL553426
A22748
h-l-abu-oh;l-2-amino-n-butyric acid;l-2-aminobutanoic acid
r-aminobutyric acid;(r)-(-)-2-amino-n-butyric acid; d-2-amino-butanoic acid;d(-)-2-aminobutyric acid
A22752
d(-)-2-aminobutyric acid
AKOS006238605
d-butyrine
d-ethylglycine
einecs 220-084-4
AKOS015923109
h-d-abu-oh
(r)-2-amino-butyric acid
AM20090323
S6330
SCHEMBL427560
h-d-2-abu-oh
J-300324
mfcd00064414
butanoic acid, 2-amino-, (2r)-
r-aminobutyric acid
CS-D1130
delta-alpha-aminobutyric acid
delta-2-aminobutyric acid
delta-(-)-2-aminobutyric acid
(2r)-2-aminobutanoate
(r)-2-amino-butanoate
delta-2-aminobutanoate
d-a-aminobutyric acid
delta-2-aminobutyrate
delta-2-aminobuttersaeure
(r)-2-amino-butanoic acid
delta-2-aminobutanoic acid
HY-Y0127
BCP17075
DS-13951
h-d-abu(2)-oh
Q27457174
DTXSID701314996
EN300-59098
Z904976986
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
alpha-aminobutyric acidAn alpha-amino acid that is butyric acid bearing a single amino substituent located at position 2.
D-alpha-amino acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID430782Displacement of [3H]glycine from strychnine-insensitive glycine recognition site of NMDA receptor in rat brain cortex membrane2009Journal of medicinal chemistry, Aug-27, Volume: 52, Issue:16
Drug design, in vitro pharmacology, and structure-activity relationships of 3-acylamino-2-aminopropionic acid derivatives, a novel class of partial agonists at the glycine site on the N-methyl-D-aspartate (NMDA) receptor complex.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-199059 (35.54)18.7374
1990's23 (13.86)18.2507
2000's30 (18.07)29.6817
2010's38 (22.89)24.3611
2020's16 (9.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.59%)5.53%
Reviews3 (1.78%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other165 (97.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]